Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate

Journal of Urology

Volumn 169, Issue 6, 2003, Pages 2160-2165

  Rosser, Charles J ^c   Levy, Lawrence B ^c   Kuban, Deborah A ^c   Chichakli, Ramsey ^c   Pollack, Alan ^a   Lee, Andrew ^c   Pisters, Louis L ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NONE

Author keywords

Disease progression; Prostate; Prostate specific antigen; Prostatic neoplasms; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RACE DIFFERENCE; RADIATION DOSE; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 0038625461     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000058212.00170.a0     Document Type: Article

References (20)

1. Greenlee, R. T., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 2000. CA Cancer J Clin, 50: 7, 2000
2. Bagshaw, M. A., Kaplan, I. D. and Cox, R. C.: Prostate cancer. Radiation therapy for localized disease. Cancer, 71: 939, 1993
3. Hanks, G. E., Hanlon, A. L., Schultheiss, T. E., Freedman, G. M., Hunt, M., Pinover, W. H. et al: Conformal external beam treatment of prostate cancer. Urology, 50: 87, 1997
4. Shipley, W. U., Thames, H. D., Sandler, H. M., Hanks, G. E., Zietman, A. L., Perez, C. A. et al: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA, 281: 1598, 1999
5. Kuban, D. A., el-Mahdi, A. M. and Schellhammer, P. F.: Prostate-specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys, 32: 307, 1995
6. Zietman, A. L., Coen, J. J., Dallow, K. C. and Shipley, W. U.: The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys, 32: 287, 1995
7. Roach, M., III, Lu, J., Pilepich, M. V., Asbell, S. O., Mohiuddin, M., Terry, R. et al: Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol, 161: 864, 1999
8. Hanlon, A. L. and Hanks, G. E.: Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation. Urology, 55: 725, 2000
9. Rosser, C. J., Smith, L. G., Chichakli, R., Levy, L. B., Pollack, A., Kuban, D. A. et al.: The effects of age on biochemical disease progression in men with carcinoma of the prostate treated with external-beam irradiation. J Urol, suppl., 165: 332, abstract 1363, 2001
10. Manual for Staging of Cancer, 4th ed. American Joint Committee on Cancer. Philadelphia: J. B. Lippincott Co., 1992
11. Zagars, G. K., Pollack, A., Kavadi, V. S. and von Eschenbach, A. C.: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys, 32: 293, 1995
12. Pollack, A., Zagars, G. K., Starkschall, G., Childress, C. H., Kopplin, S., Boyer, A. L. et al: Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys, 34: 555, 1996
13. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys, 37: 1035, 1997
14. Lee, W. R., Hanlon, A. L. and Hanks, G. E.: Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol, 156: 450, 1996
15. Hanks, G. E.: Radiotherapy or surgery for prostate cancer? Tenand fifteen-year results of external beam therapy. Acta Oncol, 30: 231, 1991
16. Dillioglugil, O., Leibman, B. D., Kattan, M. W., Seale-Hawkins, C., Wheeler, T. M. and Scardino, P. T.: Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology, 50: 93, 1997
17. McBride, C. M., Brown, B. W., Thompson, J. R., Westbrook, K. C. and Milne, C. A.: Can patients with breast cancer be cured of their disease? A sample of the M. D. Anderson Hospital experience. Cancer, 51: 938, 1983
18. Amling, C. L., Blute, M. L., Bergstralh, E. J., Seay, T. M., Slezak, J. and Zincke, H.: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol, 164: 101, 2000
19. Hanks, G. E., Krall, J. M., Hanlon, A. L., Asbell, S. O., Pilepich, M. V. and Owen, J. B.: Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys, 28: 39, 1994
20. Vicini, F. A., Kestin, L. L. and Martinez, A. A.: The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys, 45: 553, 1999